[Featured Stock] HLB Surges on News of Passing FDA Clinical Trial Inspection for Liver Cancer Drug
HLB is showing strong performance.
As of 9:47 AM on the 18th, HLB was trading at 78,800 won, up 16,500 won (26.48%) from the previous trading day.
HLB's liver cancer drug candidate, Rivoceranib, has passed the clinical trial site inspection, a hurdle it had previously failed. This is being seen as a green light for its challenge for approval in the United States.
Hot Picks Today
"Parents Deposited 10 Million Won for Me"... Se...
- "Is It Safe to Keep Using Obesity Medications?"... Startling Study Results Relea...
- "SK Hynix Stock Windfall"... Teenager With Wads of Cash Turns Thief at Jewelry S...
- "Major Crash Is Coming... Buy Even If You Have to Skip a Meal" 'Rich Dad' Shares...
- "Save 30 Million Won, Grow It to 100 Million": Dramatic Pledge Sparks "Is This a...
On the 18th, HLB announced that it received a "No Action Indicated (NAI)" rating in the FDA's Bioresearch Monitoring Inspection (BIMO). NAI means "passed."
![[Featured Stock] HLB Surges on News of Passing FDA Clinical Trial Inspection for Liver Cancer Drug](http://www.asiae.co.kr/news/img_view.htm?img=2024072208164559128_1721603806.jpg)
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
